{
    "clinical_study": {
        "@rank": "75575", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "IBU 200 mg/ PE 10 mg"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Experimental", 
                "description": "IBU 200 mg/ PE 10 mg/CHLOR 4 mg"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "arm_group_type": "Active Comparator", 
                "description": "Acetaminophen 500 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, prospective, randomized, double-blind, parallel group, comparative,\n      non-inferiority study designed to evaluate the efficacy of Ibuprofen (IBU) 200 mg/\n      Phenylephrine (PE) 10 mg and IBU 200 mg/ PE 10 mg/ Chlorpheniramine (CHLOR) 4 mg on the\n      relief of symptoms of the common cold and flu. The reference product that the active\n      treatments will be compared to is paracetamol (PARA) 500 mg."
        }, 
        "brief_title": "Evaluation of the Efficacy and Safety of Two Ibuprofen Combination Products for the Treatment of the Common Cold and Flu in Latin America", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Common Cold", 
        "condition_browse": {
            "mesh_term": "Common Cold"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Male and female subjects who are 18 years old or older at the time of screening.\n\n        Subjects who are willing and able to comply with scheduled visits, treatment plan,\n        laboratory tests, and other study procedures.\n\n        Subjects must present with a score of 5 of higher for at least 1 of the following 4\n        symptoms: runny nose, plugged nose, sneezing, or head congestion on the WURSS-21\n        assessment, within 36 hours of onset of symptoms.\n\n        Exclusion Criteria:\n\n        Anyone with a history of chronic allergic rhinitis or asthma at the time of the screening\n        visit, or with history of chronic recurrent airway disease, infections, or frequent\n        complications of colds (otitis media, sinusitis, or bronchitis)\n\n        Subjects taking any other type of cold remedies within the last 7 days prior to the\n        screening (Appendix 2), as well as those subjects who are taking antibiotics of any kind.\n\n        Subjects with a hypersensitivity to IBU, PE, or CHLOR or APAP."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938144", 
            "org_study_id": "B3971002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A", 
                "description": "Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine tablet, 4x/day, up to 12 doses.", 
                "intervention_name": "Advil Congestion Relief", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "description": "Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine/4 mg Chlorpheniramine tablet, 4x/day, up to 12 doses.", 
                "intervention_name": "Advil Allergy and Congestion Relief", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "description": "Acetaminophen 500 mg, 4x/day, up to 12 doses.", 
                "intervention_name": "Paracetamol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetaminophen", 
                "Ibuprofen", 
                "Phenylephrine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Common cold", 
            "efficacy", 
            "symptoms", 
            "Wisconsin Upper Respiratory Symptom Survey - 21", 
            "ibuprofen", 
            "phenylephrine", 
            "pseudoephedrine"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3971002&StudyName=Evaluation%20of%20the%20Efficacy%20and%20Safety%20of%20Two%20Ibuprofen%20Combination%20Products%20for%20the%20Treatment%20of%20the%20Common%20Cold%20and%20Flu%20in%20Latin%20"
        }, 
        "number_of_arms": "3", 
        "official_title": "Four-day Clinical Evaluation of the Efficacy and Safety of Two Ibuprofen Combination Products for the Symptomatic Treatment of the Common Cold and Flu", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Brazil: National Committee of Ethics Research", 
                "Brazil: National Committee of Ethics in Research"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline in the sum of 4 of the most common cold and flu symptoms (runny nose, plugged nose, sneezing and head congestion), averaged over 3 days obtained from the Wisconsin Upper Respiratory Symptom Survey - 21", 
            "measure": "Change from baseline in the sum of 4 of the most common cold and flu symptoms (runny nose, plugged nose, sneezing and head congestion), averaged over 3 days obtained from the Wisconsin Upper Respiratory Symptom Survey - 21", 
            "safety_issue": "No", 
            "time_frame": "3 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938144"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The severity of cold/flu symptoms will be determined by the subject's response to the Wisconsin Upper Respiratory Symptom Survey, which includes questions related to the signs and symptoms of cold and flu, as well as Quality of Life Measures.", 
                "measure": "Change from baseline in the sum of all 10 symptoms, averaged over 3 days.", 
                "safety_issue": "No", 
                "time_frame": "3 Days"
            }, 
            {
                "description": "The severity of cold/flu symptoms will be determined by the subject's response to the Wisconsin Upper Respiratory Symptom Survey, which includes questions related to the signs and symptoms of cold and flu, as well as Quality of Life Measures.", 
                "measure": "AM assessment of symptom relief reflective over the past 12 hours.", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "description": "The severity of cold/flu symptoms will be determined by the subject's response to the Wisconsin Upper Respiratory Symptom Survey, which includes questions related to the signs and symptoms of cold and flu, as well as Quality of Life Measures.", 
                "measure": "PM assessment of symptom relief reflective over the past 12 hours.", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "measure": "Symptom relief since taking the first dose.", 
                "safety_issue": "No", 
                "time_frame": "60 min"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}